Overview

Radiation Therapy With or Without Goserelin and Cyproterone in Treating Patients With Prostate Cancer

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
Male
Summary
RATIONALE: Radiation therapy uses high energy x rays to kill tumor cells. This may be an effective treatment for prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as goserelin and cyproterone, may lessen the amount of androgens made by the body and reduces the amount of androgens available to the body. It is not yet know whether radiation therapy alone is more effective than radiation therapy given together with goserelin and cyproterone in treating patients with prostate cancer. PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it works compared to giving radiation therapy together with goserelin and cyproterone in treating patients with prostate cancer that is at high risk for metastasis.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Treatments:
Cyproterone
Cyproterone Acetate
Goserelin
Criteria
DISEASE CHARACTERISTICS: Histologically proven prostatic adenocarcinoma of the following
TNM stages and WHO grades: T1 or T2 and grade G3 T3 or T4 and any histologic grade No
evidence of distant metastases No evidence of positive common iliac or para-aortic lymph
nodes Confirmed by bone scan, chest x-ray, negative ultrasound or CT of the liver, and CT
of the retroperitoneum and/or bipedal lymphangiography Extraperitoneal pelvic lymph node
biopsy may be either positive or negative provided stage and grade criteria are met

PATIENT CHARACTERISTICS: Age: Under 80 Performance status: WHO 0-2 Hematopoietic: Not
specified Hepatic: Not specified Renal: Not specified Other: No history of second
malignancy except basal cell skin carcinoma

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
chemotherapy for prostate cancer Endocrine therapy: No prior hormonal therapy for prostate
cancer Radiotherapy: No prior radiotherapy for prostate cancer Surgery: No prior radical
prostatectomy No prior transperitoneal lymph node staging